Cobalamin decyanation by the membrane transporter BtuM von Martínez Felices, Jose M., Barreto, Yan Borges, Thangaratnarajah, Chancievan, Whittaker, Jacob J., Alencar, Adriano M., Guskov, Albert, Slotboom, Dirk J.

Volltext

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer von Felices, M, Chu, S, Kodal, B, Bendzick, L, Ryan, C, Lenvik, A.J, Boylan, K.L.M, Wong, H.C, Skubitz, A.P.N, Miller, J.S, Geller, M.A

Volltext

Design and Application of Project-Based Learning Methodologies for Small Groups Within Computer Fundamentals Subjects von Sanchez-Romero, J. L., Jimeno-Morenilla, A., Pertegal-Felices, M. L., Mora-Mora, H.

Volltext

Organic Agricultural Practice: Crop Load Management Enhancing Quality and Storability of High-Russet Pears von Guerra, Marcos, Álvarez-Taboada, Flor, Marabel, Verónica, Felices, Amanda M, Rodríguez-González, Álvaro, Casquero, Pedro A

Volltext

Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking von Bachanova, V., Cao, Q., Miller, J., Maakaron, J., Felices, M., Wangen, R., Larson, M., Simantov, R., Mazor, R. D., Tilahun, A., Grzywacz, B.

Volltext

Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI) von Bachanova, V., Zak, J., Cao, Q., Maakaron, J., Grzywacz, B., Fletcher, C., Ayyappan, S., Hu, M., Desai, S., Felices, M., Farooq, U., Teijaro, J. R., Kenkre, V. P.

Volltext

P618: SECOND‐GENERATION CD19 TARGETING TRI‐SPECIFIC KILLER ENGAGER DRIVES ROBUST NK CELL FUNCTION AGAINST B CELL MALIGNANCIES von Miller, J., Kodal, B., Hinderlie, P., Vallera, D., Berk, G., Bachanova, V., Felices, M.

Volltext

Transcutaneous oxygen tension measurements following peripheral transluminal angioplasty procedure has more specificity and sensitivity than ankle brachial index von Pardo, M, Alcaraz, M, Bernal, F L, Felices, J M, Achel, G D, Canteras, M

Volltext

Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer von Geller, M.A, Bendzick, L.A, Ryan, C, Chu, S, Lenvik, A, Skubitz, A.P.N, Boylan, K.L.M, Isaksson Vogel, R, Miller, J, Felices, M

Volltext

Using Genetic Engineering to Improve the Bispecific Antibody Platform for MDS Therapy von Vallera, D.A, Felices, M, Sarhan, D, Brandt, L, Guldevall, K, Warlick, E.D, Cooley, S, Weisdorf, D.J, Onfelt, B, Miller, J.S

Volltext

ARID5B regulates metabolic programming in human adaptive NK cells von Cichocki, Frank, Wu, Cheng-Ying, Zhang, Bin, Felices, Martin, Tesi, Bianca, Tuininga, Katie, Dougherty, Phillip, Taras, Emily, Hinderlie, Peter, Blazar, Bruce R, Bryceson, Yenan T, Miller, Jeffrey S

Volltext

Development of Emotional Skills through Interdisciplinary Practices Integrated into a University Curriculum von Jimeno-Morenilla, Antonio, Gilar-Corbí, R., Marcos-Jorquera, Diego, Pertegal-Felices, M. L.

Volltext

Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia von Chiu, Emily, Felices, Martin, Cichocki, Frank, Davis, Zachary, Wang, Hongbo, Tuninga, Katie, Vallera, Daniel A., Lee, Tom, Bjordahl, Ryan, Malmberg, Karl Johan, Valamehr, Bahram, Miller, Jeffrey S.

Volltext

965MO GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a nov... von Miller, J.S., Warlick, E.D., Wangen, R., Zorko, N., Hinderlie, P., Lewis, D., Vallera, D.A., Felices, M.

Volltext

Intraperitoneal or subcutaneously administered IL-15 superagonist (N-803) increases NK cell cytotoxicity in ovarian cancer von Felices, M., Bendzick, L.E., Hinderlie, P., Kodal, B., Wesley, E., Miller, J.S., Geller, M.A.

Volltext

755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK... von Miller, J.S., Zorko, N., Merino, A., Phung, G., Khaw, M., Howard, P., Hamsher, H., Davis, Z., Cichocki, F., Berk, G.I., Felices, M.

Volltext

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS von Sarhan, Dhifaf, Brandt, Ludwig, Felices, Martin, Guldevall, Karolin, Lenvik, Todd, Hinderlie, Peter, Curtsinger, Julie, Warlick, Erica, Spellman, Stephen R., Blazar, Bruce R., Weisdorf, Daniel J., Cooley, Sarah, Vallera, Daniel A., Önfelt, Björn, Miller, Jeffrey S.

Volltext

17P Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers von Miller, J.S., Felices, M., Vallera, D.A., Ettestad, B., Hallstrom, C., Kodal, B., Todhunter, D.A., Arvindam, U.S., Phung, S.K., Kile, Q., Berk, G., Kennedy, P.R.

Volltext

A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses von Chan, Francis Ka-Ming, Shisler, Joanna, Bixby, Jacqueline G., Felices, Martin, Zheng, Lixin, Appel, Michael, Orenstein, Jan, Moss, Bernard, Lenardo, Michael J.

Volltext

126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies von Zorko, N., Felices, M., Merino, A., Walker, J., Kodal, B., Lenvik, A., Davis, Z.B., Lenvik, T., Tape, S., Soignier, Y., Nelson, T., Hinderlie, P., Antonarakis, E., Cichocki, F., Hwang, J., Berk, G., Miller, J.S.

Volltext